Heidi Health Secures $340M to Scale AI Agents Across Global Health Systems

Heidi Health Doubles Valuation With $340M Funding Round

Heidi Health, an Australian healthcare AI startup, announced it has raised $340 million in new funding to accelerate adoption of AI agents in health systems globally1

1

2

2

. The funding round values the company at $900 million, almost double the $465 million valuation achieved during its October Series B round2

2

3

3

. The capital injection includes a $100 million Series C funding led by Blackbird, with participation from existing investors Phoenix Court, Point72 Private Investments and Headline, plus a $240 million growth investment from General Catalyst's Customer Value Fund1

1

3

3

. This brings Heidi's total funding to more than $430 million3

3

.

Expanding Beyond Automating Clinical Notes to Agentic AI Capabilities

Co-founder and CEO Dr. Thomas Kelly emphasized that Heidi's ambition extends far beyond documentation. "From the day I started Heidi, the ambition was always bigger than writing doctor's notes. I imagined that AI would sit alongside clinicians and complete real work under their supervision. That's the shift we're now making, from documenting care to helping clinicians act on it," Kelly stated1

1

2

2

. The company plans to use the funding to deepen adoption within global health systems, add agentic AI capabilities that support work around patient visits, and build regulatory and clinical safety foundations for these new features2

2

. The startup is also expanding into markets across Asia and the Middle East while strengthening local teams in the US, UK and Australia, expecting to add as many as 150 staff over the next year to its current workforce of close to 600 people3

3

.

AI-Powered Healthcare Platform Gains Traction With Major Health Systems

Heidi's AI-driven healthcare solutions have demonstrated remarkable adoption across global health systems. The platform has supported over 175 million patient visits and more than 67 million clinical hours since its launch two years ago2

2

3

3

. The platform is now being used in 190 countries and 110 languages2

2

. Annual recurring revenue reached $50 million in April, up dramatically from $1 million about two years earlier2

2

3

3

. Since its Series B in October, Heidi has achieved an enterprise activation rate of around 62% across major public and private health systems1

1

. Notable clients include Beth Israel Lahey Health, one of Massachusetts' largest health systems, and the company was selected as the sole supplier for NHS England Midlands, representing the largest clinical AI procurement in NHS history1

1

.

Core AI Scribe and Evidence Tools Address Clinical Documentation Burden

Heidi's platform centers on its AI Scribe, which uses ambient listening to record patient history and symptoms, update records, provide multilingual support, and organize text while preparing for likely questions such as coding suggestions and extra documents like handouts1

1

2

2

. The company also released Evidence, which provides clinicians direct access to trusted medical research at the point of care1

1

. Evidence automatically factors in active patient details, uploaded lab results and live conversation transcripts to generate summaries with in-line citations linked to original sources with risk scoring, allowing clinicians to quickly guide research and spend less time reviewing tracked literature1

1

. The platform has answered more than 10 million queries since Evidence launched in March1

1

. Additional tools include Remote, the company's first secure wearable hardware device built for clinical settings from surgery to community clinics, and Dictate, a voice-to-text feature1

1

2

2

.

Healthcare AI Adoption Accelerates as Physicians Embrace Administrative Automation

The funding comes as healthcare AI adoption surges globally, particularly in the United States. According to a survey led by the American Medical Association, 81% of physicians surveyed in 2026 said they were using augmented artificial intelligence, more than double the rate from a 2023 poll1

1

. AMA CEO and Executive Vice President John Whyte, MD, MPH, noted that "AI has quickly become part of everyday medical practice. Physicians see real promise in its ability to support clinical decisions and cut down on administrative burden"1

1

. However, Whyte cautioned that most physicians remain wary of patient use for tasks requiring clinical judgment, with concerns that AI might degrade human specialists' abilities if it replaces actual expertise1

1

. Heidi appears to be addressing these concerns by designing its platform to augment rather than replace clinicians, providing administrative automation and research assistance while maintaining the foundations of trust and human insight1

1

.

Investor Confidence Reflects Strategic Model-Building Capabilities

Investors expressed strong confidence in Heidi's strategic approach and execution. Pranav Singhvi, co-founder and partner at General Catalyst's Customer Value Fund, stated that Heidi "has shown it can win trust inside the world's most complex health systems"2

2

. Michael Tolo, general partner at Blackbird, highlighted that Heidi invested early in building its own models and training capability, earning "the right to capture valuable downstream workflows in the most rigorous clinical settings globally"2

2

. The $240 million from General Catalyst's Customer Value Fund represents a debt-like financing instrument that will fund Heidi's sales and marketing costs as the startup expands, with General Catalyst receiving a return of the revenue generated from that spending up to an agreed cap, on top of its initial investment, without owning any stock or warrants3

3

. This structure reflects growing investor interest in AI tools aimed at increasing efficiency in healthcare, with similar startups like Forus raising $150 million this month and Latent securing $80 million earlier in the year3

3

.